Takeda to supply Novavax's coronavirus vaccine candidate in Japan

Takeda Pharmaceutical Co. said Friday it will produce and sell in Japan a COVID-19 vaccine being developed by U.S. biotechnology firm Novavax Inc.Novavax, which is carrying out clinical trials for the vaccine candidate, NVX-CoV2373, will license and transfer manufacturing technologies to Takeda, the two companies said.Takeda, which will receive funding from Japan's health ministry, anticipates the capacity to produce over 250 million doses of the vaccine a year.It will secure regulatory approval in Japan to supply the vaccine."Nothing is more important right now than protecting the world ag…READ FULL ARTICLE